C12N 2710/24152
Relating to complementing cells and packaging systems for producing virus or viral
Official title: relating to complementing cells and packaging systems for producing virus or viral particles
C12N2710/24152 (Relating to complementing cells and packaging systems for producing virus or viral) appears on 18 US grants and 32 published applications in this corpus.
Search patents in C12N- Granted patents
- 18
- Published applications
- 32
- Assignees
- 18
- Inventors
- 45
- Latest grant
- 28 Jan 2020
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 1 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 1 | 0 |
| 2009 | 0 | 1 |
| 2010 | 1 | 3 |
| 2011 | 0 | 3 |
| 2012 | 0 | 4 |
| 2013 | 5 | 3 |
| 2014 | 3 | 1 |
| 2015 | 3 | 0 |
| 2016 | 0 | 2 |
| 2017 | 0 | 1 |
| 2018 | 2 | 1 |
| 2019 | 1 | 3 |
| 2020 | 1 | 2 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 2 |
| 2024 | 0 | 2 |
| 2025 | 0 | 1 |
| 2026 | 0 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Viral vector manufacture28 Jan 2020US 10,544,397 B2Sementis Limited
- Intergenic sites between conserved genes in the genome of modified vaccinia ankara (MVA) vaccinia virus24 Sep 2019US 10,421,978 B2The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Whole expressed cell as antigen carrier, and use thereof in preparing vaccine or diagnostic agent, and screening monoclonal antibodies27 Nov 2018US 10,138,494 B2Formosa Biomedical Inc.
- Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites30 Jan 2018US 9,879,231 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Modified vaccinia Ankara (MVA) virus recombinants comprising heterologous coding sequences inserted into the intergenic regions between essential genes15 Sep 2015US 9,133,478 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Compositions and Methods for Enhancement of mRNA Vaccine Performance and Vaccination against Mpox18 Jun 2026US 2026/0166138 A1Yale University
- Mammalian Cell Line for the Production of Modified Vaccinia Virus Ankara (MVA)19 Mar 2026US 2026/0078353 A1Bavarian Nordic A/S
- Poxvirus-based vectors produced by natural or synthetic dna and uses thereof3 Jul 2025US 2025/0215456 A1City of Hope
- Human metapneumovirus combination vaccine31 Oct 2024US 2024/0358812 A1Valneva SE
- Human metapneumo virus vaccine6 Jun 2024US 2024/0181034 A1Valneva SE
Most cited
By later US patents
- Recombinant vaccinia viral vectors20US 6,372,455 B1Arizona Board of Regents · 2002
- Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites18US 9,133,480 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2015
- Modified vaccinia Ankara (MVA) virus recombinants comprising heterologous coding sequences inserted into the intergenic regions between essential genes15US 9,133,478 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2015
- Production of poxviruses with adherent or non adherent avian cell lines9US 7,432,101 B2Vivalis · 2008
- Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites7US 9,879,231 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2018